Zomedica Pharmaceuticals Corp (ZOM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zomedica Pharmaceuticals Corp (ZOM) has a cash flow conversion efficiency ratio of -0.050x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.65 Million) by net assets ($132.44 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ZOM stock market capitalisation for the company's overall valuation and market capitalisation.
Zomedica Pharmaceuticals Corp - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Zomedica Pharmaceuticals Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Zomedica Pharmaceuticals Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zomedica Pharmaceuticals Corp ranked by their cash flow conversion efficiency. See Zomedica Pharmaceuticals Corp cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FLUOGUIDE A/S DK -1
F:96X
|
-0.092x |
|
Unifosa
TWO:8277
|
0.064x |
|
ImmunoPrecise Antibodies Ltd.
NASDAQ:HYFT
|
-0.162x |
|
City Service SE
WAR:CTS
|
0.058x |
|
5E ADVANCED MATLS NEW
F:J9I1
|
-0.101x |
|
Pangaea Oncology S.A.
MC:PANG
|
-0.057x |
|
Hotelim Société Anonyme
PA:MLHOT
|
N/A |
|
Donkeyrepublic Holding AS
CO:DONKEY
|
0.036x |
Annual Cash Flow Conversion Efficiency for Zomedica Pharmaceuticals Corp (2013–2024)
The table below shows the annual cash flow conversion efficiency of Zomedica Pharmaceuticals Corp from 2013 to 2024. View Zomedica Pharmaceuticals Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $195.66 Million | $-23.63 Million | -0.121x | -81.45% |
| 2023-12-31 | $240.02 Million | $-15.97 Million | -0.067x | -52.50% |
| 2022-12-31 | $267.39 Million | $-11.67 Million | -0.044x | +17.18% |
| 2021-12-31 | $270.89 Million | $-14.28 Million | -0.053x | +83.43% |
| 2020-12-31 | $51.07 Million | $-16.24 Million | -0.318x | +95.74% |
| 2019-12-31 | $2.10 Million | $-15.63 Million | -7.461x | -144.76% |
| 2018-12-31 | $3.66 Million | $-11.15 Million | -3.048x | -88.54% |
| 2017-12-31 | $4.39 Million | $-7.09 Million | -1.617x | -46.52% |
| 2016-12-31 | $4.13 Million | $-4.56 Million | -1.103x | -8115.62% |
| 2015-12-31 | $3.71 Million | $-49.88K | -0.013x | +95.42% |
| 2014-12-31 | $141.41K | $-41.44K | -0.293x | +2.74% |
| 2013-12-31 | $206.38K | $-62.19K | -0.301x | -- |
About Zomedica Pharmaceuticals Corp
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital sign… Read more